Patent intelligence · US
US 10377739
Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
Patent details — US 10377739
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 13, 2019
- Expiration
- Aug 8, 2039
- Claims
- 16
- CPC classes
- A61P, A61P11/00, A61P11/02, A61P11/04
Quick answer
US 10377739 (Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives) is held by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P11/00, A61P11/02, A61P11/04, A61P31/12, A61P31/14
More from OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
Related pharmaceutical patents in our USPTO index.
-
US 12357555
Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12214019
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12168692
Antibodies targeting CCR2
granted -
US 12128133
Ingestible device with expandable enclosure
granted -
US 12077551
Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases
granted
Frequently asked questions
What is US patent 10377739?
US 10377739 (Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives) is held by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10377739?
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 148 pharmaceutical patents for this assignee.
When does US 10377739 expire?
Our index shows an expiration date of Aug 8, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.